EOLS (Evolus) Interest Income: $1.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EOLS Evolus Inc EOLS
74 GF Score
Price $7.99
GF Value $13.42
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Evolus Interest Income?

Evolus EOLS 74 Interest Income is $1.3 Mil as of Jun. 2026. GuruFocus rates EOLS with a GF Score™ of 74/100 and a GF Value™ of $13.42 (Possible Value Trap). The stock has 6 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Evolus's interest income for the three months ended in Jun. 2026 was $0.3 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $1.3 Mil.

Evolus Interest Income Historical Data

* Premium members only.

The historical data trend for Evolus's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Interest Income Chart

Evolus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.12 0.86 3.26 1.93

Evolus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.48 0.26 0.29 0.30
EOLS
74GF Score
Evolus Inc EOLS
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolus Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $1.3 Mil mean?
Evolus (EOLS) has a Interest Income of $1.3 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Evolus and its competitors.
Is Evolus' Interest Income too high?
Evolus' current Interest Income is $1.3 Mil. Overall, Evolus has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Interest Income compare to AQST and TLRY?
Evolus' Interest Income of $1.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Drug Manufacturers company?
A good Interest Income depends on the Drug Manufacturers industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Evolus and its competitors. Evolus's current Interest Income is $1.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.42, compared to a current price of $7.99 — trading 40.5% below its estimated fair value. The current Interest Income is $1.3 Mil. Evolus' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Evolus (EOLS), the current Interest Income is $1.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $7.99 is trading 40.5% below its estimated GF Value™ of $13.42. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Interest Income: $1.3 Mil
  • GF Value™: $13.42 vs. price of $7.99 (40.5% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
74GF Score

Get the complete analysis for EOLS

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price
$13.42
GF Value